Business Description
Gilead Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US3755581036
Share Class Description:
GILD: Ordinary SharesTotal Employee Number:
17,000Compare
Compare
Traded in other countries / regions
GILD.USAGILD.Canada0QYQ.UKGILD.ArgentinaGIS.GermanyGILD.MexicoGILD.AustriaGILD34.Brazil1GILD.ItalyGILD.ChileGILD.SwitzerlandGILD.Peru Index Membership
S&P 500NASDAQ 100Russell 1000Russell 3000MSCI World Index IPO Date
1992-01-22Description
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.35 | |||||
Equity-to-Asset | 0.42 | |||||
Debt-to-Equity | 0.94 | |||||
Debt-to-EBITDA | 1.53 | |||||
Interest Coverage | 11.84 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 4.81 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2.8 | |||||
3-Year EBITDA Growth Rate | 15.5 | |||||
3-Year EPS without NRI Growth Rate | 3.9 | |||||
3-Year FCF Growth Rate | 4.5 | |||||
3-Year Book Growth Rate | 2.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.15 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.53 | |||||
9-Day RSI | 58.18 | |||||
14-Day RSI | 56.59 | |||||
3-1 Month Momentum % | -8.86 | |||||
6-1 Month Momentum % | 0.43 | |||||
12-1 Month Momentum % | 15.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.97 | |||||
Quick Ratio | 1.77 | |||||
Cash Ratio | 0.81 | |||||
Days Inventory | 107.7 | |||||
Days Sales Outstanding | 58.72 | |||||
Days Payable | 41.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.35 | |||||
Dividend Payout Ratio | 0.38 | |||||
3-Year Dividend Growth Rate | 2.7 | |||||
Forward Dividend Yield % | 2.41 | |||||
5-Year Yield-on-Cost % | 2.72 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 3.31 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 79.35 | |||||
Operating Margin % | 40.03 | |||||
Net Margin % | 31 | |||||
EBITDA Margin % | 48.72 | |||||
FCF Margin % | 34.41 | |||||
OCF Margin % | 36.34 | |||||
ROE % | 43.23 | |||||
ROA % | 16.11 | |||||
ROIC % | 21.96 | |||||
3-Year ROIIC % | -21.27 | |||||
ROC (Joel Greenblatt) % | 179.87 | |||||
ROCE % | 25.63 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 18.29 | |||||
Forward PE Ratio | 42.65 | |||||
PE Ratio without NRI | 16.04 | |||||
Shiller PE Ratio | 27.05 | |||||
Price-to-Owner-Earnings | 19.92 | |||||
PEG Ratio | 1.59 | |||||
PS Ratio | 5.66 | |||||
PB Ratio | 7.09 | |||||
Price-to-Free-Cash-Flow | 16.45 | |||||
Price-to-Operating-Cash-Flow | 15.58 | |||||
EV-to-EBIT | 15.44 | |||||
EV-to-Forward-EBIT | 123.91 | |||||
EV-to-EBITDA | 12.51 | |||||
EV-to-Forward-EBITDA | 62.45 | |||||
EV-to-Revenue | 6.09 | |||||
EV-to-Forward-Revenue | 6.05 | |||||
EV-to-FCF | 17.71 | |||||
Price-to-GF-Value | 1.4 | |||||
Price-to-Projected-FCF | 1.61 | |||||
Price-to-Median-PS-Value | 1.53 | |||||
Earnings Yield (Greenblatt) % | 6.48 | |||||
FCF Yield % | 6.14 | |||||
Forward Rate of Return (Yacktman) % | 9.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GILD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gilead Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 29,734 | ||
| EPS (TTM) ($) | 7.34 | ||
| Beta | -0.0028 | ||
| 3-Year Sharpe Ratio | 0.68 | ||
| 3-Year Sortino Ratio | 1.24 | ||
| Volatility % | 22.06 | ||
| 14-Day RSI | 56.59 | ||
| 14-Day ATR ($) | 4.038904 | ||
| 20-Day SMA ($) | 129.5325 | ||
| 12-1 Month Momentum % | 15.3 | ||
| 52-Week Range ($) | 107.75 - 157.29 | ||
| Shares Outstanding (Mil) | 1,241.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gilead Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gilead Sciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 16:30 | In 105 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 104 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 21 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 20 days | ||
| USD 0.820000 Cash Dividend | 2026-06-15 | 125.59 (-0.43%) | ||
| Goldman Sachs Annual Global Healthcare Conference | 2026-06-09 13:20 | 128.10 (-1.51%) | ||
| Bernstein Annual Strategic Decisions Conference | 2026-05-28 11:00 | 133.69 (-0.10%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-19 11:00 | 129.67 (-0.37%) | ||
| BofA Securities Health Care Conference | 2026-05-12 14:20 | 133.52 (+1.92%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 136.30 (+2.19%) |
Show
Entries
Gilead Sciences Inc Frequently Asked Questions
What is Gilead Sciences Inc(GILD)'s stock price today?
The current price of GILD is $134.28. The 52 week high of GILD is $157.29 and 52 week low is $107.75.
When is next earnings date of Gilead Sciences Inc(GILD)?
The next earnings date of Gilead Sciences Inc(GILD) is 2026-08-07 Est..
Does Gilead Sciences Inc(GILD) pay dividends? If so, how much?
The Dividend Yield %  of Gilead Sciences Inc(GILD) is 2.35% (As of Today), Highest Dividend Payout Ratio of Gilead Sciences Inc(GILD) was 0.67. The lowest was 0.16. And the median was 0.39. The  Forward Dividend Yield % of Gilead Sciences Inc(GILD) is 2.41%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NAS:GILD
No articles.
Press Release
Articles on Gilead Sciences Inc
A Look at Gilead Sciences Inc (GILD) After 3.7% Decline -- GF Value $96.09 vs Price $129.83
Jul 10, 2026
Headlines
See More- 1
Jul 16, 2026
Kalshi offers wagers on clinical trials and drug approvals
Seeking Alpha • 8:29am
Jul 08, 2026
White House weighing contenders for FDA's top job
Seeking Alpha • 4:12pm
Healthcare breadth hits 15-year high, but XLV’s top holdings remain Quant Holds
Seeking Alpha • 6:00am
Jul 06, 2026
WHO begins experimental Ebola trial as Congo outbreak claims 500+ lives
Seeking Alpha • 10:16am
Jun 25, 2026
Record-setting healthcare M&A activity to extend through H2: PwC
Seeking Alpha • 12:59pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers